The effect of (-)eburnamonine in chronic cerebrovascular disorders has been evaluated with a neuropsychological methodology combined with a computerized EEG-pharmacological methodology. A two-part study was carried out in 8 patients with chronic cerebrovascular insufficiency: an acute treatment with (-)eburnamonine 40 mg intravenously and a chronic treatment with (-)eburnamonine 20 mg intravenously daily for 10 days and 60 mg orally daily during the 20 days following period. In the acute study, the modification of EEG power spectrum analysis - decrease of the delta and theta bands and increase of the alpha band - confirmed the drug passage through the blood-brain barrier and the influence of the drug on brain bioelectrical activity. In the chronic study, a statistically significant decrease in the delta band and in the theta band and a statistically significant increase in the alpha 2 band confirmed previous results. Concerning clinical and neuropsychological parameters, after 30 days of therapy, there was a decrease in the HRSD total score and an improvement in clinical symptoms, especially in mood depression, vigilance, cooperation and anxiety, as shown by PBRSM.
|Number of pages||12|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1982|
ASJC Scopus subject areas